TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
One Percent Rule Checklist For Safer Forex Trading Risk 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
CARLSBAD, Calif., April 21, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release first quarter 2017 financial results after the close of trading on Thursday, May 4, 2017. The Company’s management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 2407268. The webcast will also be available on the SeaSpine website following the completion of the call. To listen to the webcast, please visit the investor relations section of the SeaSpine website at www.seaspine.com.
About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact Lynn Pieper Lewis (415) 937-5402 [email protected]
